[Mastopathy and endometrial hyperplasia--coexistence, relationships]

Samples of endometrium were examined histologically in 161 female patients with endometrial hyperplasia or mastopathy. Moreover, LH, FSH, prolactin, testosterone, and dehydroepiandrosterone sulphate levels were assayed in 51 patients. Mastopathy was found in 36.8% of patients with endometrial hyperplasia. An estimate risk of mastopathy within 13 years following a diagnosis of endometrial hyperplasia is 33%. Endometrial hyperplasia accompanied mastopathy in 24.8% of cases, and an estimated risk of endometrial hyperplasia within 21 years following a diagnosis of mastopathy is 37%. Hormonal status of patients with endometrial hyperplasia-mastopathy is similar to that in patients with endometrial and breast cancer. The authors suggest that both endometrial hyperplasia and mastopathy should be considered markers of the risk of uterine and breast cancer.